 NEW YORK, Nov. 03, 2022 GLOBE NEWSWIRE -- IN8bio, Inc. Nasdaq: INAB, a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced positive early data from the ongoing Phase 1 trial evaluating INB-100, an allogeneic gamma-delta T cell therapy, in patients with high-risk acute myeloid leukemia AML undergoing haploidentical hematopoietic stem cell transplant HSCT have been selected for a poster presentation at the 64th American Society of Hematology ASH Annual Meeting and Exposition taking place December 10-13, 2022. 